Search our Innovation Portfolio

A method to quickly and automatically separate viable bacteria from the other constituents of positive blood cultures, enabling them to be processed in iFAST's revolutionary Antimicrobial Susceptibility Testing system. We use patented impedance flow cytometry to determine the most appropriate antibiotics to treat bacterial infections, giving results in 2-3 hours compared with 2-3 days with current clinical methods. This will save thousands of lives, improve outcomes and help antimicrobial stewardship.

The technology behind FluoCDx leverages modular DNA probes, customizable for precise species recognition and broad gram-type bacterial detection. Within 5 minutes of adding a sample, the initial fluorescence signal quantitatively confirms infection. After 30 minutes, changes in fluorescence reveal antibiotic susceptibility: an increase indicates resistance, while a decrease or stable signal confirms susceptibility. This innovative approach ensures rapid, reliable diagnostics, enabling precise treatment decisions.

Our technology will provide an alternative to existing technologies to reduce urinary catheter blockage and infections. It is cheaper, more efficient and does not require the use of any antibiotics, thereby eliminating the possibility of promoting antimicrobial resistance development or lacking efficacy against AMR bacteria.